Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period.
Total revenue grew 3% year-over-year in the first quarter, driven primarily by the continued performance of TRIKAFTA, KAFTRIO and an early contribution from the U.S. launch of ALYFTREK.
Revenue climbed 9% year-over-year in the U.S., but fell 5% year-over-year outside the U.S. The company noted that the international decline was expected, citing a “violation of its intellectual property rights” in Russia that is expected to be a “limited and isolated matter.”
“Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&D pipeline,” said Reshma Kewalramani, president and CEO of Vertex.
“With multiple programs in pivotal development including povetacicept, which continues to make rapid progress in achieving its potential as a pipeline-in-a-product, and additional programs in early and mid-stage development, Vertex is poised to continue to deliver value for years to come.”
Vertex ended the quarter with $11.4 billion in cash, cash equivalents and marketable securities, up from $11.2 billion at the end of 2024.
Guidance: Vertex Pharmaceuticals raised its full-year 2025 revenue guidance from a range of $11.75 billion to $12 billion to a new range of $11.85 billion to $12 billion versus estimates of $11.97 billion, according to Benzinga Pro.
Vertex executives are currently discussing details from the quarter on a call with investors and analysts that started at 4:30 p.m. ET.
VRTX Price Action: Vertex Pharmaceuticals shares were down 3.04% after-hours, trading at $485 at the time of publication on Monday, according to Benzinga Pro.
Read Next:
Photo: Courtesy of Vertex Pharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.